论文部分内容阅读
目的分析探讨小剂量普伐他汀与非诺贝特联合治疗混合型高血脂症临床疗效及安全性。方法选取2014年1月—2015年1月在本院接受高血脂治疗混合型高血脂症患者66例,随机分组,一组为参照组,共33例,使用普伐他汀与非诺贝特进行治疗,非诺贝特的用量为200 mg,每日清晨服用一次,普伐他汀的用量为20 mg,每日晚餐服用一次,而另一组为研究组,共33例,也使用普伐他汀与非诺贝特进行治疗,非诺贝特用量同参照组,普伐他汀的用量为10 mg,每日晚餐服用一次,两组均治疗3个月。观察评价的指标为总胆固醇、甘油三酯、低密度脂蛋白以及不良反应率。其中计数资料使用χ2检验,计量资料使用t检验,P<0.05为差异有统计学意义。结果研究组患者的低密度脂蛋白为(3.10±0.34)mmol/L、甘油三酯为(1.58±0.07)mmol/L、总胆固醇为(4.98±0.45)mmol/L,而参照组患者的低密度脂蛋白为(4.12±0.23)mmol/L、甘油三酯为(2.98±0.67)mmol/L、总胆固醇为(6.31±1.21)mmol/L,研究组各指标均较参照组低,两组对比差异均有统计学意义(均P<0.05)。研究组不良反应发生率为24.24%,参照组不良反应发生率为54.55%,研究组的混合型高血脂症患者不良反应情况显著低于参照组,差异有统计学意义(P<0.05)。结论小剂量普伐他汀与非诺贝特联合治疗混合型高血脂症不仅临床疗效好,且安全性高,值得推广使用。
Objective To investigate the clinical efficacy and safety of low-dose pravastatin combined with fenofibrate in the treatment of mixed hyperlipidemia. Methods Sixty-six patients with hyperlipidemia who were treated with hyperlipidemia in our hospital from January 2014 to January 2015 were randomly divided into control group (n = 33 in each group) and pravastatin combined with fenofibrate Treatment, the fenofibrate was 200 mg, taken once daily during the early morning, the dosage of pravastatin 20 mg, taken once daily dinner, while the other study group, a total of 33 patients also used pravastatin With fenofibrate treatment, the amount of fenofibrate with the reference group, the amount of pravastatin 10 mg, taken once daily dinner, both were treated for 3 months. Observed and evaluated the indicators of total cholesterol, triglycerides, low density lipoprotein and adverse reaction rate. Among them, count data were tested byχ2 test, measurement data were analyzed by t test, P <0.05 was considered statistically significant. Results In the study group, LDL was (3.10 ± 0.34) mmol / L, triglyceride was (1.58 ± 0.07) mmol / L and total cholesterol was (4.98 ± 0.45) mmol / L, (4.12 ± 0.23) mmol / L, (2.98 ± 0.67) mmol / L and total cholesterol (6.31 ± 1.21) mmol / L, respectively. The indexes of the study group were lower than those of the reference group The differences were statistically significant (all P <0.05). The incidence of adverse reactions in the study group was 24.24%, and the incidence of adverse reactions in the reference group was 54.55%. The adverse reactions in the study group were significantly lower than those in the reference group (P <0.05). Conclusion Low-dose pravastatin combined with fenofibrate in the treatment of mixed hyperlipidemia not only has good clinical efficacy, but also has high safety and is worth popularizing.